# Observational Urinary Bladder cancer studies: 104 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 104 trials that are observational for Urinary Bladder cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational Urinary Bladder cancer studies: 104 rows for $5.20, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/urinary-bladder-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 104
- Recruiting or not yet: 104
- Read on: November 19, 2026

## Trials

The 25 newest of 104, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931924 | Functional Outcomes of the Miami Pouch Continent Cutaneous Urinary Diversion: A Quality of Life Study | Hospices Civils de Lyon | Observational | Not yet recruiting | Urinary Diversion, Urinary Bladder Carcinoma, Neurogenic Bladder, Pelvic Malignancy, Urinary Incontinence | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931924) |
| October 26, 2026 | NCT07893509 | Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in... | Bladder Cancer Advocacy Network | Observational | Not yet recruiting | NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer | 1,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893509) |
| October 22, 2026 | NCT07888374 | Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification | Ruijin Hospital | Observational | Recruiting | Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer | 477 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888374) |
| September 15, 2026 | NCT07820566 | Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney... | University Hospital, Strasbourg, France | Observational | Recruiting | Kidney Cancers, Bladder Cancer, Prostate Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820566) |
| August 25, 2026 | NCT07784387 | A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal | Janssen-Cilag Farmaceutica Ltda. | Observational | Recruiting | Urinary Bladder Neoplasms | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784387) |
| August 24, 2026 | NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) | Amsterdam UMC, location VUmc | Observational | Recruiting | Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782164) |
| July 31, 2026 | NCT07739121 | Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739121) |
| July 30, 2026 | NCT07735793 | A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea | Janssen Korea, Ltd., Korea | Observational | Recruiting | Urinary Bladder Neoplasms | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735793) |
| July 29, 2026 | NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | University of Oklahoma | Observational | Not yet recruiting | Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732686) |
| July 24, 2026 | NCT07726602 | Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial | OHSU Knight Cancer Institute | Observational | Recruiting | Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726602) |
| July 23, 2026 | NCT07721935 | Development of an AI-Agent for Urological Disease Diagnosis and Treatment | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Recruiting | Urinary Stones, Prostate Cancer, Bladder Cancer | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721935) |
| June 29, 2026 | NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer | Convergent Genomics, Inc. | Observational | Recruiting | Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673016) |
| May 29, 2026 | NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | Henan Provincial People's Hospital | Observational | Recruiting | Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC) | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614594) |
| May 22, 2026 | NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | Oslo University Hospital | Observational | Recruiting | Bladder Cancer, Urothelial Carcinoma (UC), Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602010) |
| May 15, 2026 | NCT07589413 | Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT | Sponsor not shown (see the record) | Observational | Recruiting | Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Recurrence, Progression of Bladder Cancer, Transurethral... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589413) |
| May 12, 2026 | NCT07581496 | T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer | University Hospital, Basel, Switzerland | Observational | Recruiting | Bladder Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581496) |
| April 22, 2026 | NCT07545694 | Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Recruiting | Bladder Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545694) |
| April 14, 2026 | NCT07529639 | Tumor Budding and T1 Substaging in Urothelial Bladder Cancer | Assiut University | Observational | Not yet recruiting | Urothelial Bladder Carcinoma, Bladder Carcinoma, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529639) |
| April 13, 2026 | NCT07525349 | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer | Assiut University | Observational | Not yet recruiting | Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525349) |
| April 7, 2026 | NCT07514897 | Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Observational | Recruiting | Bladder Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514897) |
| April 7, 2026 | NCT07514143 | Bladder EpiCheck Product Development Study | Nucleix Ltd. | Observational | Recruiting | Suspicion of Bladder Cancer, NMIBC Surveillance | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514143) |
| March 31, 2026 | NCT07503795 | Outcomes of Definitive Radiotherapy for Bladder Cancer | Sohag University | Observational | Not yet recruiting | Bladder Cancer (BC) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503795) |
| March 13, 2026 | NCT07468838 | Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer | Institut Cancerologie de l'Ouest | Observational | Not yet recruiting | Prostate Cancer, Bladder Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468838) |
| February 20, 2026 | NCT07424560 | Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer | Sponsor not shown (see the record) | Observational | Recruiting | Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424560) |
| February 9, 2026 | NCT07395037 | A Study of Ward Admissions for Haematuria | British Urology Researchers in Surgical Training | Observational | Recruiting | Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer, Renal Cancer, Urothelial Carcinoma | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395037) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 5 |
| Qilu Hospital of Shandong University | 4 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 4 |
| IRCCS San Raffaele | 3 |
| Cedars-Sinai Medical Center | 3 |
| Peking University First Hospital | 2 |
| [Photocure](https://specstream.ai/data/clinical-trials/company/photocure) | 2 |
| Regina Elena Cancer Institute | 2 |
| University of Kansas Medical Center | 2 |
| Centre Hospitalier Universitaire, Amiens | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| University of Washington | 2 |
| Mayo Clinic | 2 |
| Assiut University | 2 |
| Vastra Gotaland Region | 2 |
| Yonsei University | 2 |
| Universitaire Ziekenhuizen KU Leuven | 2 |
| Prospective Bladder Cancer Infrastructure Foundation | 1 |
| British Urology Researchers in Surgical Training | 1 |
| Lahey Clinic | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Convergent Genomics, Inc. | 1 |
| Early is Good Inc. | 1 |
| Johns Hopkins University | 1 |
| Ruijin Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 39 |
| China | 21 |
| Italy | 9 |
| France | 8 |
| United Kingdom | 5 |
| Germany | 4 |
| Japan | 4 |
| South Korea | 4 |
| Netherlands | 3 |
| Belgium | 3 |
| Canada | 3 |
| Puerto Rico | 2 |
| Norway | 2 |
| Sweden | 2 |
| Australia | 2 |
| Hong Kong | 1 |
| Finland | 1 |
| Switzerland | 1 |
| Portugal | 1 |
| Egypt | 1 |
| Poland | 1 |
| Russia | 1 |
| Spain | 1 |
| Hungary | 1 |
| Denmark | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Whiskey bars in the United States](https://specstream.ai/data/businesses/whiskey-bars/united-states)
- [Cosmetology schools in the United States](https://specstream.ai/data/businesses/cosmetology-schools/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
